by The Tutu Team | Apr 6, 2017 | Uncategorized
Source: Breast Cancer Research Foundation Science News CDK4/6 inhibitors are a new class of drugs that have shown promise in the treatment of advanced ER- positive breast cancer. Cyclin dependent kinases (CDK) regulate the process of cell division, required for... 
by The Tutu Team | Mar 23, 2017 | Uncategorized
Author: Ines Martins / Source: Breast Cancer News Adding the CDK4/6 inhibitor abemaciclib to Faslodex (fulvestrant) is a promising way to treat patients with an advanced breast cancer who experienced a relapse or had their disease progress after endocrine... by The Tutu Team | Oct 11, 2016 | Uncategorized
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.1 The... by The Tutu Team | Oct 11, 2016 | Uncategorized
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved progression-free survival in postmenopausal women with hormone receptor–positive advanced breast cancer, reported Hortobagyi et al at the 2016 European Society for... 
by The Tutu Team | Jun 25, 2016 | Uncategorized
Background: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments... 